These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
216 related articles for article (PubMed ID: 24228135)
1. Prognostic value of cancer stem cell marker CD133 expression in non-small cell lung cancer: a systematic review. Qu H; Li R; Liu Z; Zhang J; Luo R Int J Clin Exp Pathol; 2013; 6(11):2644-50. PubMed ID: 24228135 [TBL] [Abstract][Full Text] [Related]
2. The role of CD133 expression in the carcinogenesis and prognosis of patients with lung cancer. Le H; Zeng F; Xu L; Liu X; Huang Y Mol Med Rep; 2013 Nov; 8(5):1511-8. PubMed ID: 24008862 [TBL] [Abstract][Full Text] [Related]
3. Predictive and prognostic effect of CD133 and cancer-testis antigens in stage Ib-IIIA non-small cell lung cancer. Su C; Xu Y; Li X; Ren S; Zhao C; Hou L; Ye Z; Zhou C Int J Clin Exp Pathol; 2015; 8(5):5509-18. PubMed ID: 26191258 [TBL] [Abstract][Full Text] [Related]
4. Prognostic impact of cancer stem cell-related markers in non-small cell lung cancer patients treated with induction chemoradiotherapy. Shien K; Toyooka S; Ichimura K; Soh J; Furukawa M; Maki Y; Muraoka T; Tanaka N; Ueno T; Asano H; Tsukuda K; Yamane M; Oto T; Kiura K; Miyoshi S Lung Cancer; 2012 Jul; 77(1):162-7. PubMed ID: 22387005 [TBL] [Abstract][Full Text] [Related]
5. The combination of stem cell markers CD133 and ABCG2 predicts relapse in stage I non-small cell lung carcinomas. Li F; Zeng H; Ying K Med Oncol; 2011 Dec; 28(4):1458-62. PubMed ID: 20717756 [TBL] [Abstract][Full Text] [Related]
6. Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Bertolini G; Roz L; Perego P; Tortoreto M; Fontanella E; Gatti L; Pratesi G; Fabbri A; Andriani F; Tinelli S; Roz E; Caserini R; Lo Vullo S; Camerini T; Mariani L; Delia D; Calabrò E; Pastorino U; Sozzi G Proc Natl Acad Sci U S A; 2009 Sep; 106(38):16281-6. PubMed ID: 19805294 [TBL] [Abstract][Full Text] [Related]
7. Prognostic value of cancer stem cell marker CD133 expression in gastric cancer: a systematic review. Wen L; Chen XZ; Yang K; Chen ZX; Zhang B; Chen JP; Zhou ZG; Mo XM; Hu JK PLoS One; 2013; 8(3):e59154. PubMed ID: 23533603 [TBL] [Abstract][Full Text] [Related]
8. Differential Expression of Cancer Stem Cell Markers ALDH1 and CD133 in Various Lung Cancer Subtypes. Roudi R; Korourian A; Shariftabrizi A; Madjd Z Cancer Invest; 2015; 33(7):294-302. PubMed ID: 26046383 [TBL] [Abstract][Full Text] [Related]
9. Is CD133 expression a prognostic biomarker of non-small-cell lung cancer? A systematic review and meta-analysis. Wu H; Qi XW; Yan GN; Zhang QB; Xu C; Bian XW PLoS One; 2014; 9(6):e100168. PubMed ID: 24940615 [TBL] [Abstract][Full Text] [Related]
10. Relevant markers of cancer stem cells indicate a poor prognosis in hepatocellular carcinoma patients: a meta-analysis. Ma YC; Yang JY; Yan LN Eur J Gastroenterol Hepatol; 2013 Sep; 25(9):1007-16. PubMed ID: 23478672 [TBL] [Abstract][Full Text] [Related]
11. [Expression of CD133 and Notch1 in non-small cell lung cancer and the clinicopathological significance]. Zhou L; Wu S; Yu L; Gong X; Song W; Cheng Z Nan Fang Yi Ke Da Xue Xue Bao; 2015 Feb; 35(2):196-201. PubMed ID: 25736112 [TBL] [Abstract][Full Text] [Related]
12. The roles of CD133 expression in the patients with non-small cell lung cancer. Wang D; Wen GM; Hou W; Xia P Cancer Biomark; 2018; 22(3):385-394. PubMed ID: 29758924 [TBL] [Abstract][Full Text] [Related]
13. High CD133 expression in the nucleus and cytoplasm predicts poor prognosis in non-small cell lung cancer. Huang M; Zhu H; Feng J; Ni S; Huang J Dis Markers; 2015; 2015():986095. PubMed ID: 25691807 [TBL] [Abstract][Full Text] [Related]
14. The prognostic value of CD133 expression in non-small cell lung cancer: a meta-analysis. Wang W; Chen Y; Deng J; Zhou J; Zhou Y; Wang S; Zhou J Tumour Biol; 2014 Oct; 35(10):9769-75. PubMed ID: 24973892 [TBL] [Abstract][Full Text] [Related]
15. The role of CD133 in the identification and characterisation of tumour-initiating cells in non-small-cell lung cancer. Tirino V; Camerlingo R; Franco R; Malanga D; La Rocca A; Viglietto G; Rocco G; Pirozzi G Eur J Cardiothorac Surg; 2009 Sep; 36(3):446-53. PubMed ID: 19464919 [TBL] [Abstract][Full Text] [Related]
16. CD133 is a temporary marker of cancer stem cells in small cell lung cancer, but not in non-small cell lung cancer. Cui F; Wang J; Chen D; Chen YJ Oncol Rep; 2011 Mar; 25(3):701-8. PubMed ID: 21174061 [TBL] [Abstract][Full Text] [Related]
17. The intratumoral distribution influences the prognostic impact of CD68- and CD204-positive macrophages in non-small cell lung cancer. Li Z; Maeda D; Yoshida M; Umakoshi M; Nanjo H; Shiraishi K; Saito M; Kohno T; Konno H; Saito H; Minamiya Y; Goto A Lung Cancer; 2018 Sep; 123():127-135. PubMed ID: 30089583 [TBL] [Abstract][Full Text] [Related]
18. Clinicopathological significance of cancer stem cells marked by CD133 and KAI1/CD82 expression in laryngeal squamous cell carcinoma. Yu L; Zhou L; Wu S; Gong X; Feng Z; Ma L; Zhu B; Yao N; Wang D; Dong H World J Surg Oncol; 2014 Apr; 12():118. PubMed ID: 24758564 [TBL] [Abstract][Full Text] [Related]
19. CD133 is indicative for a resistance phenotype but does not represent a prognostic marker for survival of non-small cell lung cancer patients. Salnikov AV; Gladkich J; Moldenhauer G; Volm M; Mattern J; Herr I Int J Cancer; 2010 Feb; 126(4):950-8. PubMed ID: 19676044 [TBL] [Abstract][Full Text] [Related]
20. Prognostic value of cancer stem cell marker CD133 expression in pancreatic ductal adenocarcinoma (PDAC): a systematic review and meta-analysis. Li X; Zhao H; Gu J; Zheng L Int J Clin Exp Pathol; 2015; 8(10):12084-92. PubMed ID: 26722393 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]